title: Autoimmunotherapy of type II diabetes with soluble low-molecular-mass antigens: a case report.
abstract: OBJECTIVE
  To study whether autoimmunization of patients suffering from non-insulin-dependent Type II diabetes with soluble low-molecular-mass antigens (LMA) isolated from their serum will activate the immune system and improve clinical status.
  
  
  METHODS
  From March 1998 to July 2000, the patient was treated, under observation, with LMA isolated from that same patient. Doses for injections varied between 2 and 5 mg of LMA. Injections were performed at weekly or monthly intervals. Biochemical studies were performed before injections and 1 to 2 weeks after them. The following biochemical parameters were determined in the blood: levels of glucose, insulin-competitive auto-antibodies (ICAA), a-glutamine acid decarboxylase (GAD), total concentration of LMA and of the 66 kDa and 51 kDa proteins as main representatives of the LMA isolated.
  
  
  RESULTS
  The patient suffered from high blood glucose levels (BGL), ICAA, GAD, hemoglobin Alc and, especially, of LMA and their proteins. Shortarm immunotherapy did not improve the parameters studied. However, a regular monthly injection of LMA at a dose of 3.5 to 4 mg significantly decreased BGL and reduced the concentrations of LMA and their proteins. The whole clinical status of the patient improved and became more stable.
  
  
  CONCLUSIONS
  We suggest that vaccination of a diabetic patient with LMA activates the host immune system, thereby preventing progress of the disease.
authors: Department of Hematology, Hadassah-Hebrew University Hospital, Jerusalem, Israel.
authors: Michael
authors: M
authors: Ginzburg
authors: Alexandr
authors: A
authors: Vol
authors: Patricia
authors: P
authors: Smirnoff
authors: Bella
authors: B
authors: Sandler
authors: Itshak
authors: I
authors: Zusman
mesh_terms: D001324:Autoantigens / Q000097:blood / Q000276:immunology*; D001786:Blood Glucose; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000276:immunology / Q000628:therapy*; D004306:Dose-Response Relationship, Immunologic; D005968:Glutamate Decarboxylase / Q000097:blood; D006801:Humans; D007167:Immunotherapy; D007330:Insulin Antibodies / Q000097:blood; D008297:Male; D008875:Middle Aged; D008970:Molecular Weight; D016896:Treatment Outcome; D014611:Vaccination
chemical_list: D001324:Autoantigens; D001786:Blood Glucose; D007330:Insulin Antibodies; D005968:Glutamate Decarboxylase